Stockscreener 앱 받기
87.81
0.87%
-0.82
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit expansion - jammulinksnews.com
What drives Rhythm Pharmaceuticals Inc. stock priceConsistently outstanding ROI - jammulinksnews.com
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN
Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru
Is Rhythm Pharmaceuticals Inc. a good long term investmentHigh-octane financial growth - jammulinksnews.com
What analysts say about Rhythm Pharmaceuticals Inc. stockGame-changing returns - jammulinksnews.com
Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest
Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada
(RYTM) Investment Analysis - news.stocktradersdaily.com
Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada
Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN
Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN
Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest
Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest
Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire
Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN
Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest
Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest
Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest
Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks
RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan
Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN
Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus
Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN
Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India
Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail
Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada
Guggenheim Raises Rhythm Pharmaceuticals (RYTM) Price Target Ami - GuruFocus
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st
Rhythm Pharmaceuticals (RYTM) Shares Slide Following Stock Offering - GuruFocus
Rhythm Pharmaceuticals Prices Public Offering Of 2.06 Mln Shares At $85 Per Share - Nasdaq
Rhythm Pharmaceuticals prices upsized public offering at $85 per share By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
0.65%
자본화:
|
볼륨(24시간):